Sulpiridum
Sulpiryd Hasco tablets are used to treat severe mental disorders. The medicine prevents the action of certain substances in the brain, which leads to the alleviation of disease symptoms. The active substance of the medicine, sulpiride, has antipsychotic and antidepressant effects and belongs to the group of so-called neuroleptics, benzamide derivatives. Sulpiryd Hasco is used to treat:
1/8
Before starting treatment with Sulpiryd Hasco, discuss it with your doctor or pharmacist. In some patients, sulpiride has caused motor agitation when used in high doses. In the phase of aggression or agitation, small doses of the medicine may exacerbate such symptoms. Caution should be exercised in case of hypomania (a state of elevated mood, characterized by increased energy, reduced need for sleep, increased physical and mental efficiency). In aggressive or agitated patients who also experience impulsivity, sulpiride-containing medicines can be administered together with an appropriately selected sedative by the doctor. Particular caution should be exercised when using sulpiride in patients with Parkinson's disease, for whom neuroleptic treatment is necessary. In a small number of patients, extrapyramidal symptoms (e.g., hand tremors, head, sudden muscle contractions, inability to sit or stay in one place, strange, rhythmic uncontrolled movements, most often in the face) and restlessness (akathisia) may occur, and the doctor may recommend reducing the dose of the medicine or using anti-Parkinsonian medicines. Similarly, as with other neuroleptic medicines, the possibility of a severe side effect, namely neuroleptic malignant syndrome (characterized by, among other things, increased body temperature, muscle stiffness, instability of the autonomic nervous system, impaired consciousness, increased activity of certain enzymes in the blood, such as creatine kinase), which can be life-threatening, should be taken into account. In case of such symptoms, all antipsychotic medicines, including sulpiride, should be discontinued. After sudden discontinuation of antipsychotic medicines, acute symptoms may occur, including nausea, vomiting, increased sweating, and insomnia. There may also be a recurrence of the disease and the occurrence of involuntary movements (akathisia, dystonia, dyskinesia). Therefore, it is recommended to gradually discontinue the medicine. Neuroleptics can lower the seizure threshold. After using sulpiride, cases of seizures have been reported in patients who had not previously experienced them. During sulpiride treatment, caution should be exercised in patients with unstable epilepsy, and patients with a history of seizures should be closely monitored. The dosage of antiepileptic medicines should not be changed in patients who require concomitant use of sulpiride. As with other medicines that are mainly excreted by the kidneys, caution should be exercised when using sulpiride in patients with renal impairment. The dose of sulpiride should be reduced and adjusted gradually. Sulpiride may increase the risk of serious heart rhythm disorders, namely ventricular arrhythmias. Caution should be exercised when using sulpiride in patients with heart rhythm disorders and cardiovascular disorders. Sulpiride should be avoided in combination with other neuroleptics. 2/8 Caution should be exercised when using this medicine, especially if the patient or their family members have a history of venous thrombosis. The use of this type of medicine is associated with the risk of venous thrombosis. Sulpiride should be used with caution in patients at risk of stroke. Elderly patients Usually, the same doses are used as in younger adults, but elderly patients may be more prone to certain sulpiride side effects, such as orthostatic hypotension, excessive sedation, and extrapyramidal symptoms. Therefore, in these patients, sulpiride, like other neuroleptic medicines, should be used with caution. In elderly patients with impaired renal function, the doctor will recommend an appropriate dose reduction, depending on the patient's condition. Patients with renal and/or hepatic impairment In patients with impaired renal and/or hepatic function, the doctor will recommend an appropriate dose reduction, depending on the patient's condition.
Due to the lack of sufficient clinical data, sulpiride should not be used in children and adolescents under 14 years of age.
Tell your doctor about all medicines you are currently taking or have recently taken, as well as any medicines you plan to take. Sulpiryd Hasco should not be used with levodopa-containing medicines. During treatment with Sulpiryd Hasco, avoid consuming any alcoholic beverages and medicines containing alcohol.
3/8
Sulpiryd Hasco should be taken at least 1 hour before a meal or 2 hours after a meal, as the presence of food reduces the absorption of the medicine. During treatment with Sulpiryd Hasco, avoid consuming any alcoholic beverages and medicines containing alcohol.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to have a child, consult your doctor before taking this medicine. Pregnancy Do not use sulpiride during pregnancy. Newborns exposed to antipsychotic medicines (including amisulpride, similar to sulpiride) during the third trimester of pregnancy are at risk of side effects, including extrapyramidal symptoms and/or withdrawal symptoms. The severity of these symptoms may vary depending on the severity of the disease and the duration of delivery. Observed symptoms include agitation, increased or decreased muscle tone, tremors, drowsiness, respiratory distress syndrome, or feeding disorders. Newborns should be closely monitored. Breastfeeding Do not use sulpiride in breastfeeding women. Sulpiride passes into human milk in sufficient quantities to cause pharmacological effects in the child.
Patients, especially those who drive vehicles and operate machinery, should be warned about the possibility of drowsiness associated with the use of this medicine.
If you have previously been diagnosed with intolerance to some sugars, consult your doctor before taking this medicine. Each Sulpiryd Hasco 50 mg film-coated tablet contains 20 mg of lactose. Each Sulpiryd Hasco 100 mg film-coated tablet contains 40 mg of lactose. Each Sulpiryd Hasco 200 mg film-coated tablet contains 80 mg of lactose.
This medicine should always be taken according to the doctor's instructions. If you have any doubts, consult your doctor or pharmacist.
4/8 If you feel that the effect of Sulpiryd Hasco is too strong or too weak, consult your doctor or pharmacist. Schizophrenia The usual initial dose is 400-800 mg per day, divided into two doses (morning and early evening), depending on the severity of symptoms. The maximum daily dose is 1200 mg. Only in cases of treatment-resistant disorders may the psychiatrist increase the daily dose to 1600 mg, divided into doses. Depressive disorders The usual initial dose is 50-150 mg per day. Then the dose is increased to 150-300 mg per day. Elderly patients The same doses are usually used as in younger adults. In elderly patients with impaired renal function, the dose of the medicine should be reduced. Patients with renal impairment The dose of sulpiride should be adjusted accordingly; depending on the degree of renal function, the dose should be reduced or the interval between doses prolonged. Sulpiryd Hasco tablets are best taken with water. Sulpiride should not be taken in the late evening hours (after 4 pm), due to the possibility of sleep disturbances. Sulpiride should not be taken simultaneously or within 2 hours of taking antacids or sucralfate.
In case of taking a higher dose of Sulpiryd Hasco than recommended or accidental ingestion of the medicine by another person, immediately consult a doctor, pharmacist, or the nearest hospital. Take the remaining tablets and the leaflet with you to show the doctor, who will decide on further action, depending on the dose taken and the symptoms of overdose. Symptoms of overdose include excessive sedation, restlessness, confusion (disorientation), impaired consciousness, agitation, extrapyramidal symptoms (e.g., hand tremors, head, sudden muscle contractions, inability to sit or stay in one place, strange, rhythmic uncontrolled movements, most often in the face), and hypotension. Coma may occur. As with poisoning with other oral medicines, activated charcoal can be administered shortly after ingestion to reduce absorption, and the doctor may perform gastric lavage. If necessary, the patient will be monitored and treated symptomatically in a hospital setting. If necessary, the doctor will recommend appropriate symptomatic treatment (e.g., administer anti-Parkinsonian medicines).
Do not take a double dose to make up for a missed dose. If you miss a dose, take it as soon as possible. If it is almost time for the next dose, do not take the missed dose.
Do not stop taking this medicine without first consulting your doctor. If you have any further doubts about taking this medicine, consult your doctor or pharmacist. 5/8 If necessary, the doctor will determine the appropriate way to stop treatment, depending on the individual patient's response to sulpiride treatment. Sulpiride administration should be discontinued immediately only in case of neuroleptic malignant syndrome (see "Warnings and precautions") or hypersensitivity (see "When not to take Sulpiryd Hasco").
Like all medicines, Sulpiryd Hasco can cause side effects, although not everybody gets them. Blood clots in the veins, especially in the legs (symptoms include swelling, pain, redness of the legs) can travel through the bloodstream to the lungs, causing chest pain and difficulty breathing. If you experience such symptoms, consult your doctor immediately. If you experience fever without a justified reason, stop taking Sulpiryd Hasco and consult your doctor. The side effects of sulpiride are listed below by system and organ class and frequency, if available: Very common - occurs in more than 1 in 10 patients Common - occurs in less than 1 in 10 patients Uncommon - occurs in less than 1 in 100 patients Rare - occurs in less than 1 in 1,000 patients Very rare - occurs in less than 1 in 10,000 patients Frequency not known - frequency cannot be estimated from available data.
Cardiac disorders Single cases: torsades de pointes (a type of ventricular tachycardia). Endocrine disorders Frequency not known: hyperprolactinemia (elevated prolactin levels in the blood), amenorrhea, gynecomastia (breast enlargement in men), sexual indifference, and impotence. Hepatic and biliary disorders Very rare: increased liver enzyme activity. Nervous system disorders Common: sedation, drowsiness. Rare: extrapyramidal symptoms and acute dyskinesia, late dyskinesia (rhythmic involuntary movements, mainly of the tongue and/or facial muscles) observed, as with other neuroleptics, after long-term treatment. Anticholinergic anti-Parkinsonian medicines are ineffective in such cases and may even exacerbate symptoms, neuroleptic malignant syndrome (see "Warnings and precautions"). Reproductive system and breast disorders Frequency not known: galactorrhea (any milk secretion in men or women, unrelated to pregnancy), amenorrhea, gynecomastia. Eye disorders Rare: rotational eye movements. 6/8 Vascular disorders Frequency not known: orthostatic hypotension. During treatment with antipsychotic medicines, cases of venous thrombosis, including deep vein thrombosis, have been reported. Gastrointestinal disorders Frequency not known: excessive salivation. Musculoskeletal and connective tissue disorders Rare: spastic neck torsion, jaw tension. Pregnancy, puerperium, and perinatal period Neonatal withdrawal syndrome (see "Pregnancy and breastfeeding"). Diagnostic tests Single cases: prolonged QT interval in the ECG. General disorders and administration site conditions Frequency not known: neuroleptic malignant syndrome, which can be life-threatening (as with all neuroleptics), weight gain. Skin and subcutaneous tissue disorders Very rare: maculopapular rash. In elderly patients with dementia, taking antipsychotic medicines, there is a small increase in mortality compared to those not treated with such medicines.
If you experience any side effects, including any side effects not listed in this leaflet, tell your doctor or pharmacist. Side effects can be reported directly to the Department of Drug Safety Monitoring, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products: Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: 22 49 21 301, fax: 22 49 21 309, website: https://smz.ezdrowie.gov.pl. Side effects can also be reported to the marketing authorization holder. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep the medicine out of sight and reach of children. Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the month. Store in a temperature below 25°C. Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
7/8
Sulpiryd Hasco 50 mg are white, round, biconvex tablets with beveled edges. One pack of Sulpiryd Hasco 50 mg contains 24, 30, 60, or 120 tablets in a cardboard box. Sulpiryd Hasco 100 mg are white, oval, biconvex tablets. One pack of Sulpiryd Hasco 100 mg contains 24, 30, 60, or 120 tablets in a cardboard box. Sulpiryd Hasco 200 mg are white, oval, biconvex tablets with a smooth surface on one side and a score line on the other side. One pack of Sulpiryd Hasco 200 mg contains 12, 30, 60, or 120 tablets in a cardboard box.
Hasco-Lek S.A., 51-131 Wrocław, ul. Żmigrodzka 242 E, Poland. Information about the medicine tel.: 22 742 00 22, e-mail: informacjaoleku@hasco-lek.pl
8/8
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.